Novo Nordisk Just Dropped 'Nordisk' After 37 Years — And It's a Desperate Move to Win Back the Obesity Market from Eli Lilly

 Novo Nordisk Just Dropped 'Nordisk' After 37 Years — And It's a Desperate Move to Win Back the Obesity Market from Eli Lilly

**The company that invented the weight-loss drug market is now losing it. On Monday, Novo Nordisk announced it's rebranding to just "Novo," rolling out a new corporate culture, and changing its iconic bull logo to look the other way. It's the first major rebrand in 37 years. And it's happening because Eli Lilly is eating Novo's lunch.**

---

## The Announcement That Says Everything

Let me start with the headline. Novo Nordisk — the Danish drugmaker behind Ozempic and Wegovy — is now just "Novo" for day-to-day purposes. The legal name stays Novo Nordisk A/S, but the brand you'll see on packaging, marketing, and communications is shorter, cleaner, and more consumer-friendly.

There's a new tagline, too: **"Lasting Health Starts Now"**.

And then there's "The Novo Way" — a four-principle cultural framework built around **customer obsession, competitiveness, clarity, and care and integrity**.

If that sounds like corporate buzzword bingo, here's the translation: Novo is admitting it got slow, complacent, and out-competed. And it's trying to fix that.

CEO Mike Doustdar told Denmark's TV2 that the rebrand is part of an effort to **"reinvent the company"**. He explained the shift in a way that cuts right to the heart of what's happening in the obesity market.

"People who use insulin are only considered as patients," he said. "But over the past four or five years, we've seen the emergence of a bigger and bigger group that tells us, 'I'm not a patient, I'm not sick. I just want to lose weight'".

That's the whole game right there. Novo spent a century building a pharmaceutical company. Now it's competing in a consumer market. And it's losing.

---

## The Market Share Bloodbath

Let me give you the numbers, because they explain why a 100-year-old company is changing its name and its logo.

In the second quarter of 2026, Novo held **38.8%** of the U.S. obesity drug market. Eli Lilly held **60.9%**.

That's not a lead. That's a blowout.

And it wasn't always this way. Novo was first. It brought Ozempic to market in 2017 and Wegovy in 2021. It created the category. Lilly came years later with Mounjaro and Zepbound.

But Lilly moved faster. It was nimbler. It innovated not just with the drugs but with how it sold them. And it took the lead in what's now the largest pharmaceutical market in history.

The stock tells the same story. Novo shares are down about **15% this year** and roughly **22.6% over the past year**. Lilly's shares are up **49.1%** over the same period.

Novo's stock just logged its worst week since February. And the company lost more than half its value in 2025 — its worst annual performance since 1984.

---

## The Rebrand Itself: What Actually Changed

Let me walk you through the specifics, because the details matter.

**The name.** "Novo" becomes the everyday operating name. "Novo Nordisk A/S" remains the legal global name. The original name dates back to the **1989 merger** of two competing Danish pharmaceutical companies: Novo Terapeutisk Laboratorium and Nordisk Insulinlaboratorium.

**The logo.** The company's iconic Apis bull — a symbol that's been part of Novo's identity for decades — is staying, but it's being tweaked. The bull now looks to the **right** instead of the left.

There's a competitive subtext here that's hard to miss. Eli Lilly has also been leaning into a single-name identity, dropping the word "Eli" from its marketing materials. Novo is following the same playbook.

**The culture.** "The Novo Way" has been rewritten. The old version emphasized accountability for financial, environmental, and social performance, fostering a healthy work environment, and innovating for patients and society.

The new version is about **customer obsession, competitiveness, clarity, and care and integrity**. Translation: move faster, compete harder, simplify decision-making.

Tania Sabroe, Novo's executive vice president of people, organization and corporate affairs, tied the brand and culture changes together: **"Our updated culture will enable us to move with focus and speed"**.

---

## The Human Element: Why This Rebrand Is Really About You

Here's the thing about this rebrand that most coverage is missing. It's not just about Novo. It's about a fundamental shift in how weight-loss drugs are sold, and who they're sold to.

Doustdar said it directly: the obesity market "acts a lot more as a consumer business than a traditional medication".

Think about what that means. When you're selling insulin to a diabetic patient, you're selling to someone who needs a medical treatment. When you're selling Wegovy to someone who wants to lose 20 pounds, you're selling to a consumer. A consumer who can choose between your product and a competitor's. A consumer who sees ads, reads reviews, and makes decisions based on price, convenience, and branding.

That's why the rebrand matters. Novo is trying to build a consumer brand, not just a pharmaceutical one. It's trying to be memorable. Relevant. Trusted.

But here's the hard truth: a new name and a new slogan don't change prescription volumes. As BMO Capital Markets analyst Evan David Seigerman put it: **"A new name, logo, and slogan must be accompanied by a true strategic change"**.

The rebrand is a communications event. The real test comes on **September 21**, when Doustdar faces investors at Novo's Capital Markets Day in London.

---

## The Oral Wegovy Bright Spot

There is one genuinely good story in Novo's recent performance, and it's worth highlighting because it shows what the company can do when it executes.

In January 2026, Novo launched an **oral version of Wegovy** in the United States. It's a pill instead of an injection. And it's been a hit.

By mid-July, the oral Wegovy had surpassed **5 million cumulative U.S. prescriptions**, with weekly prescriptions exceeding **265,000**.

In the first half of 2026, oral Wegovy contributed **DKK 5.47 billion** (about **$855 million**). In the second quarter alone, it brought in about **$500 million**.

The pill reached the market **ahead of Lilly's competing oral weight-loss drug, Foundayo**. That head start gave Novo breathing room in the direct-to-consumer channel, where patients often choose a treatment before consulting a specialist.

And direct-to-consumer is a big deal. According to Novo, DTC channels account for about **30% of injectable GLP-1 volumes** and **90% of Wegovy-pill volumes**.

But here's the catch. Even with that head start, oral Wegovy's second-quarter sales of **$494 million** merely met expectations. It's a bright spot, but it's not yet a game-changer.

---

## The Pipeline Setbacks

If the oral Wegovy launch is the good news, the pipeline is the bad news.

Novo recently **scrapped three trials** on an experimental cardiovascular drug called **Ziltivekimab**. The company halted two more trials involving the drug because of a "low likelihood" of demonstrating meaningful benefits.

That followed a late-stage failure in July. The move weakened Novo's effort to develop major growth drivers beyond diabetes and obesity.

And there's more. Novo's next-generation obesity injection, **CagriSema**, again trailed Lilly's Zepbound in a recent comparison.

The oral market is also getting more crowded. Structure Therapeutics' Aleniglipron delivered weight loss of up to **16%** in an extended study.

The message is clear: Novo is not just losing the current market. It's at risk of losing the next one too.

---

## The Restructuring: 9,000 Jobs Gone

The rebrand doesn't exist in a vacuum. It's part of a broader restructuring that has reshaped Novo over the past year.

CEO Mike Doustdar took over in **August 2025**, replacing longtime CEO Lars Fruergaard Jørgensen.

Since then, Novo has announced about **9,000 job cuts** — roughly **11% of its workforce**. It was the largest corporate layoff in Danish history.

The company also fired its CEO and largely replaced its board. Former employees told MarketWatch that Novo's culture was slow to change and that leadership often made strategic decisions based on Lilly's actions rather than its own.

That's the culture Doustdar is trying to fix with "The Novo Way."

---

## The Financial Picture: A Mixed Bag

Let me give you the numbers, because they tell a nuanced story.

In the first half of 2026, Novo reported total revenue of **DKK 175.3 billion** — about **$27.4 billion**. That's up **13% at constant currencies**. Net profit attributable to shareholders was **DKK 69.5 billion** (about **$10.9 billion**), up **25.2%**.

In the second quarter alone, adjusted sales hit **DKK 78.5 billion** (about **$12.1 billion**), up **7%**. Adjusted operating profit was **DKK 33.4 billion** (about **$5.15 billion**), up **11%** — significantly above the **DKK 28.7 billion** analysts expected.

The semaglutide franchise — which includes Wegovy injection, oral Wegovy, Ozempic, and Rybelsus — totaled **DKK 112.2 billion** (about **$17.5 billion**) in the first half. That was slightly down from the same period in 2025.

Here's the breakdown:

- **Wegovy injection**: DKK 37.7 billion (~$5.89 billion), up 7%

- **Ozempic injection**: DKK 59.2 billion (~$9.25 billion), down 2%

- **Oral Ozempic and Rybelsus**: DKK 9.8 billion (~$1.53 billion), down 9%

The pressure is real. In the U.S., Wegovy injection volumes are still growing, but sales fell **22%** year-over-year because of price cuts.

Novo did raise its full-year 2026 guidance. It now expects adjusted sales and operating profit growth of **-6% to 0%** at constant currencies, up from the previous range of **-12% to -4%**.

But the upper end of that range is still zero growth. Novo is likely to end 2026 with negative growth.

---

## The Bull Logo and the Symbolism

Let me come back to the logo for a moment, because it's a detail that tells you a lot.

The Apis bull — a symbol rooted in ancient Egyptian mythology — has been part of Novo's identity for decades. It represents strength, fertility, and regeneration. And in its previous form, it faced **left**.

Now it faces **right**.

In branding, direction matters. A left-facing animal is often read as looking backward — at history, at heritage. A right-facing animal is read as looking forward — at the future, at growth.

Novo is saying, symbolically, that it's moving forward. But moving forward requires more than a flipped logo.

---

## The Competitive Reality: Lilly Is Winning

Let me be blunt about what's happening here. Novo invented this market. Lilly is taking it.

Lilly's Zepbound and Mounjaro have been eating Novo's lunch. They've been shown to produce greater weight loss, they've been marketed more aggressively, and they've captured the bulk of new prescriptions in the United States.

Lilly's stock is up **49.1%** over the past year. Novo's is down **22.6%**.

The market has spoken. And right now, it's saying Lilly.

Novo's response has been to cut cash prices, expand direct sales, and refocus on obesity, diabetes, and related cardiometabolic diseases. It's also leaning into its oral Wegovy head start and its partnership with Costco, Amazon, and WeightWatchers to broaden access.

But the company is playing catch-up. And it knows it.

Doustdar acknowledged as much at the J.P. Morgan Healthcare Conference in January. He said 2025 was the year Novo had to accept that **"we're no longer on our own, and we need to hurry up"**.

---

## The September 21 Test

Here's the thing about Monday's rebrand announcement. It's happening one week before Novo's **Capital Markets Day in London** on September 21.

That's where Doustdar will lay out his full strategy. And that's where the rebrand either acquires substance or doesn't.

Investors will be looking for three things:

**Pipeline timelines beyond semaglutide.** Novo needs to show it can develop a second blockbuster beyond Wegovy and Ozempic. The Ziltivekimab failures have raised doubts about that.

**An update on the cancelled cardiovascular program.** The company scrapped three trials on Ziltivekimab. Investors want to know what went wrong and what the path forward looks like.

**A plan to close the market share gap with Lilly.** The oral Wegovy head start is a start, but it's not enough. Novo needs a broader strategy for winning back prescriptions.

As BMO's Seigerman put it: next week's meeting **"must bring substance and strategic direction to support a sustainable organization into the 2030s and beyond"**.

The rebrand is the warm-up. The strategy is the main event.

---

## What This Means for You

So why should you, an average American, care about a Danish drugmaker changing its name?

**If you use Wegovy or Ozempic**, the rebrand won't change your medication. The drug is the same. The pill is the same. But it may change how Novo markets to you. The company is shifting toward a consumer-focused model, with more direct-to-consumer advertising and partnerships with retailers like Costco and Amazon.

**If you're an investor**, Novo is a stock in transition. It's cheap relative to Lilly, but it's facing real headwinds. The rebrand signals a recognition of the problem. Whether it signals a solution depends on September 21.

**If you're watching the obesity market**, this is the story of a pioneer getting disrupted. Novo created the category. Now it's fighting to stay relevant in it. That's a story that repeats across industries, from tech to retail. It's always instructive to watch how incumbents respond.

**If you're just a person trying to make sense of the economy**, this is a reminder that even the most successful companies can lose their edge. Novo had a near-monopoly on weight-loss drugs. Now it's a distant second. Markets move fast. Brands have to move faster.

---

## The Bottom Line: A Name Change Is Not a Strategy

Novo Nordisk dropping "Nordisk" after 37 years is a signal. It's a signal that the company knows it's losing. It's a signal that it's willing to change. And it's a signal that the stakes are high.

But a new name, a new logo, and a new slogan are not a strategy. They're a rebrand. The strategy comes next week.

CEO Mike Doustdar has a tough job. He's trying to rebuild a company that lost its way. He's trying to compete with a rival that's faster and more aggressive. He's trying to convince investors that Novo can be great again.

The rebrand is the first step. The Capital Markets Day is the test.

For now, the market is skeptical. Novo's stock is down. Lilly is up. And the company that invented the weight-loss drug market is playing catch-up.

As BMO's Seigerman wrote: **"A new name, logo, and slogan must be accompanied by a true strategic change"**.

Next week will tell us if Novo has one.

---

## Frequently Asked Questions (FAQs)

### 1. What exactly did Novo Nordisk announce?

Novo Nordisk announced it's rebranding to "Novo" for day-to-day use, keeping "Novo Nordisk A/S" as its legal name. It also introduced a new tagline — "Lasting Health Starts Now" — and a cultural framework called "The Novo Way," based on four principles: customer obsession, competitiveness, clarity, and care and integrity.

### 2. Why is Novo rebranding now?

The company is losing market share to Eli Lilly. In the second quarter of 2026, Novo held **38.8%** of the U.S. obesity drug market, compared to Lilly's **60.9%**. The rebrand is part of a broader effort to become leaner, faster, and more consumer-focused.

### 3. What is "The Novo Way"?

"The Novo Way" is Novo's new cultural framework. It's built on four principles: **customer obsession, competitiveness, clarity, and care and integrity**. The company says the framework will help it move with focus and speed in an increasingly competitive market.

### 4. What happened to the bull logo?

The Apis bull logo is staying, but it's been tweaked. The bull now looks to the **right** instead of the left.

### 5. How is Novo performing financially?

In the first half of 2026, Novo reported revenue of **DKK 175.3 billion** (about **$27.4 billion**), up 13% at constant currencies. Net profit was **DKK 69.5 billion** (about **$10.9 billion**), up 25.2%. But the stock is down about 15% this year, and the company lost more than half its value in 2025.

### 6. What's the oral Wegovy pill?

Oral Wegovy is a pill form of the weight-loss drug. It launched in the U.S. in January 2026 and surpassed **5 million cumulative prescriptions** by mid-July. In the second quarter alone, it brought in about **$500 million**.

### 7. What pipeline setbacks has Novo faced?

Novo scrapped **three trials** on an experimental cardiovascular drug called Ziltivekimab because of a "low likelihood" of demonstrating meaningful benefits. Its next-generation obesity injection, CagriSema, also trailed Lilly's Zepbound in a recent comparison.

### 8. What happens next?

Novo will hold its **Capital Markets Day in London on September 21**, where CEO Mike Doustdar is expected to lay out the company's full strategy. That's where investors will learn whether the rebrand is backed by real strategic change.

---

## Disclaimer

*This article is for informational and educational purposes only and does not constitute financial, investment, tax, or medical advice. The views expressed are based on publicly available information, including company announcements, news reports, and analyst commentary as of September 14, 2026. Stock prices, market conditions, and company strategies are subject to rapid change. The author does not endorse any specific investment strategies or products. Past performance is not indicative of future results. Before making any financial or investment decisions based on the content of this article, please consult with qualified professionals who can evaluate your specific situation.*